<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sodium bicarbonate: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sodium bicarbonate: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sodium bicarbonate: Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="9928" href="/d/html/9928.html" rel="external">see "Sodium bicarbonate: Drug information"</a> and <a class="drug drug_patient" data-topicid="11869" href="/d/html/11869.html" rel="external">see "Sodium bicarbonate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F1062178"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Alkalinizing Agent, Oral</span>;</li>
<li>
<span class="list-set-name">Alkalinizing Agent, Parenteral</span>;</li>
<li>
<span class="list-set-name">Antacid</span>;</li>
<li>
<span class="list-set-name">Electrolyte Supplement, Oral</span>;</li>
<li>
<span class="list-set-name">Electrolyte Supplement, Parenteral</span>;</li>
<li>
<span class="list-set-name">Sodium Salt</span></li></ul></div>
<div class="block don drugH1Div" id="F53462587"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Rapid administration at a high concentration may be associated with fluctuation in cerebral blood flow and possibly intracerebral brain hemorrhage; efficacy results variable; carefully consider clinical need before administering (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18829808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18829808'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d73b4940-94c8-457d-b8da-b428566ee843">Metabolic acidosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Metabolic acidosis:</b> Limited data available: Dosage should be based on the following formula if blood gases and pH measurements are available. These equations provide an estimated replacement dose. The underlying cause and degree of acidosis may result in the need for larger or smaller replacement doses. In most cases, the initial goal of therapy is to target a pH of ~7.2 to prevent overalkalinization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16736443','lexi-content-ref-Doherty.1','lexi-content-ref-Fuhrman.1','lexi-content-ref-Carrillo-Lopez.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16736443','lexi-content-ref-Doherty.1','lexi-content-ref-Fuhrman.1','lexi-content-ref-Carrillo-Lopez.1'])">Ref</a></span>): IV:</p>
<p style="text-indent:-2em;margin-left:4em;">HCO<sub>3</sub>
<sup>- </sup>(mEq) deficit = 0.3 × weight (kg) × base deficit (mEq/L) <b>or</b></p>
<p style="text-indent:-2em;margin-left:4em;">HCO<sub>3</sub>
<sup>- </sup>(mEq) deficit = 0.3 to 0.5 × weight (kg) × [desired HCO<sub>3</sub>
<sup>-</sup> mEq/L) − measured serum HCO<sub>3</sub>
<sup>- </sup>(mEq/L)]</p>
<p style="text-indent:-2em;margin-left:4em;">Usual dosage: IV: 1 to 2 mEq/kg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Domonoske.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Domonoske.1'])">Ref</a></span>). In 27 asphyxiated neonates, a fixed dose of 1.8 mEq/kg/dose over 3 to 5 minutes administered within first 5 minutes of life did not show clinical benefit (eg, survival, acid-base status, neurodevelopmental outcomes) compared to control group (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15036741','lexi-content-ref-15318251']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15036741','lexi-content-ref-15318251'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F221628"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dose should be individualized to patient response and target parameters for condition being treated.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f772a56c-31df-49a1-a9e1-b90e664c0ba1">Antacid</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Antacid: Note:</b> Chronic antacid therapy not recommended for management of gastroesophageal reflux disease in pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23629618','lexi-content-ref-29470322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23629618','lexi-content-ref-29470322'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents: Powder for solution: Oral: <sup>1</sup>/<sub>2</sub> teaspoonful in 4 ounces of water/dose; may repeat up to every 2 hours; maximum daily dose: 6 doses/<b>day</b>; do not use maximum dose for longer than 2 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="53cc0949-02bb-49b8-8008-334d1b76084b">Cardiac arrest</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cardiac arrest (PALS guidelines):</b> Limited data available: Infants, Children, and Adolescents: IV, Intraosseous: 1 mEq/kg/dose; repeat doses should be guided by arterial blood gases; per the manufacturer, the 4.2% (0.5 mEq/mL) solution may be preferred in infants and children &lt;2 years of age. <b>Note:</b> If intraosseous route is used for administration and is subsequently used to obtain blood samples for acid-base analysis, results will be inaccurate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956230'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: Routine use of sodium bicarbonate (NaHCO<sub>3</sub>) in cardiac arrest is not recommended. </b>May be considered in the setting of prolonged cardiac arrest only after adequate alveolar ventilation has been established and effective cardiac compressions. Sodium bicarbonate may be indicated in some cardiac arrest situations (eg, hyperkalemia, sodium channel blocker toxicity [eg, tricyclic antidepressant overdose]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956230','lexi-content-ref-33081526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956230','lexi-content-ref-33081526'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1968e269-d851-497c-ac52-6e439dfb593c">Chronic kidney disease acidosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic kidney disease (CKD) acidosis:</b> Limited data available: <b>Note:</b> Initiate if serum bicarbonate &lt;22 mEq/L:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: Initial dose based on serum bicarbonate levels (see following equation); calculate the deficit to determine dose needed; may divide dose for tolerability; adjust dose to maintain serum bicarbonate within the targeted normal range (eg, children: 22 to 23 mEq/L; adults: 24 to 25 mEq/L); undertreatment should be avoided due to negative effects of acidosis on growth (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.2012','lexi-content-ref-20526632']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.2012','lexi-content-ref-20526632'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">HCO<sub>3</sub>
<sup>- </sup>(mEq) deficit = 0.5 × weight (kg) × [desired HCO<sub>3</sub>
<sup>-</sup> (mEq/L) − measured serum HCO<sub>3</sub>
<sup>- </sup>(mEq/L)]</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4dec27f3-d9d5-402b-8ff1-b796b24ea554">Hyperkalemia; adjunct</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia; adjunct:</b> Limited data available; efficacy results variable: Infants, Children, and Adolescents: IV or Intraosseous: 1 to 2 mEq/kg/dose (maximum dose: 50 mEq/dose) has been used to redistribute extracellular potassium into cells; not recommended for routine use for cardiac arrest (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kaspar.1','lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kaspar.1','lexi-content-ref-31871244'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="29bce769-41ef-4a99-a613-750b733595a2">Metabolic acidosis, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Metabolic acidosis, acute:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Blood-gas directed dosing (equations):</i> Infants, Children, and Adolescents: IV: These equations provide an estimated replacement dose. The underlying cause and degree of acidosis may result in the need for larger or smaller replacement doses. In most cases, the initial goal of therapy is to target a pH of ~7.2 to prevent overalkalinization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16736443','lexi-content-ref-Fuhrman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16736443','lexi-content-ref-Fuhrman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">HCO<sub>3</sub>
<sup>- </sup>(mEq) deficit = 0.3 × weight (kg) × base deficit (mEq/L) <b>or</b></p>
<p style="text-indent:-2em;margin-left:6em;">HCO<sub>3</sub>
<sup>- </sup>(mEq) deficit = 0.3 to 0.5 × weight (kg) × [desired HCO<sub>3</sub>
<sup>-</sup> (mEq/L) − measured serum HCO<sub>3</sub>
<sup>- </sup>(mEq/L)]</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-directed dosing (if acid-base status is not available):</i> Infants, Children, and Adolescents: IV, Intraosseous: 0.5 to 1 mEq/kg/dose over 5 to 15 minutes; maximum dose: 50 mEq/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244'])">Ref</a></span>). Subsequent doses should be based on patient's acid-base status.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0bffa3e7-7ebd-46ab-8a63-c432e6ae5e62">Neutralization local anesthetic, dental</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutralization local anesthetic (lidocaine with epinephrine), dental:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Neutralizing additive: Mix 10 parts anesthetic (lidocaine with epinephrine) to 1 part 8.4% sodium bicarbonate.</p>
<p style="text-indent:-2em;margin-left:6em;">Add 0.18 mL 8.4% sodium bicarbonate to 1.8 mL cartridge of lidocaine 2% with epinephrine 1:50,000 <b>or</b> 1:100,000.</p>
<p style="text-indent:-2em;margin-left:6em;">Add 2 mL 8.4% sodium bicarbonate to 20 mL vial of lidocaine 2% with epinephrine 1:100,000.</p>
<p style="text-indent:-2em;margin-left:6em;">Add 3 mL 8.4% sodium bicarbonate to 30 mL vial of lidocaine 2% with epinephrine 1:100,000.</p>
<p style="text-indent:-2em;margin-left:6em;">Add 5 mL 8.4% sodium bicarbonate to 50 mL vial of lidocaine 2% with epinephrine 1:100,000.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="235296af-ee32-43e4-9c56-88374332be35">Overdose, sodium channel blocker</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Overdose, sodium channel blocker (eg, tricyclic antidepressant [TCA]):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 1 to 2 mEq/kg/dose; may repeat in 5 minutes if no response, followed by continuous IV infusion of 150 mEq NaHCO<sub>3</sub>/L solution to maintain targeted pH. <b>Note:</b> Goal pH of 7.5 to 7.55 is recommended in TCA poisoning with hypotension, widened QRS interval &gt;100 ms, or ventricular arrhythmia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f45e942-2de1-4433-a269-dbe8a637db6e">Renal tubular acidosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal tubular acidosis (RTA):</b> Limited data available: <b>Note:</b> Dose should be individualized based on urinary bicarbonate excretion (degree depends on type of RTA), serum bicarbonate, and possibly age-related factors.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Distal; type 1:</i> Oral: Usual dose: 3 to 4 mEq bicarbonate/kg/<b>day</b> in divided doses; titrate to maintain normal electrolyte concentrations; younger patients require more bicarbonate replacement due to acid production during growth; some data suggest infants require a higher dose of 5 to 10 mEq bicarbonate/kg/<b>day</b> and growing children need 4 to 8 mEq bicarbonate/kg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33770395','lexi-content-ref-12138150','lexi-content-ref-7131138','lexi-content-ref-3777038','lexi-content-ref-27188519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33770395','lexi-content-ref-12138150','lexi-content-ref-7131138','lexi-content-ref-3777038','lexi-content-ref-27188519'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Proximal, type 2:</i> Oral: Usual dose: 10 to 15 mEq/kg/<b>day</b> in divided doses; titrate as necessary to maintain normal electrolyte concentrations; doses as high as 20 mEq bicarbonate/kg/<b>day</b> have been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11483854','lexi-content-ref-12138150','lexi-content-ref-27188519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11483854','lexi-content-ref-12138150','lexi-content-ref-27188519'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="91caa717-0755-498b-b9a9-9c8153859b1d">Skin protectant; relief of minor irritation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin protectant; relief of minor irritation: Note:</b> Notify physician if no symptom resolution within 14 days, or if symptoms reappear after an initial resolution.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents: Topical: Powder for solution (baking soda):</p>
<p style="text-indent:-2em;margin-left:6em;">Bath soak: Topical: Dissolve 1 to 2 cups of powder in tub of warm water and soak for 10 to 30 minutes; pat skin dry (do not rub).</p>
<p style="text-indent:-2em;margin-left:6em;">Compress or wet dressing: Topical: Mix powder with water; soak clean, soft cloth in mixture and apply cloth loosely to affected area for 15 to 30 minutes; may repeat as needed or as directed by physician.</p>
<p style="text-indent:-2em;margin-left:6em;">Paste: Topical: Mix powder with water to form a paste and apply to the affected area of skin as needed.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51893993"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution; can cause sodium retention.</p></div>
<div class="block dohp drugH1Div" id="F51893994"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution, especially in clinical states associated with edema and sodium retention.</p></div>
<div class="block doa drugH1Div" id="F221615"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9928" href="/d/html/9928.html" rel="external">see "Sodium bicarbonate: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-4em;margin-left:6em;">
<b>Safety: </b>Avoid extravasation; tissue necrosis may occur due to hypertonicity and alkalinity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33141794']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33141794'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Each 650 mg oral tablet contains ~7.7 mEq of sodium and 7.7 mEq of bicarbonate; each ½ teaspoon of powder contains sodium bicarbonate 2,616 mg, which is equal to 31.1 mEq of sodium bicarbonate. Each mL of 8.4% IV product provides 1 mEq/mL of sodium and 1 mEq/mL of bicarbonate.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f772a56c-31df-49a1-a9e1-b90e664c0ba1">Antacid</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Antacid:</b>
<b>Oral:</b> 650 mg to 2.6 g every 4 hours as needed; maximum daily dose: 15.6 g/day. Do not use maximum dosage for &gt;2 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aad9b572-996a-4dfa-ad6c-f0ae8f7aa4ec">Cardiac arrest, prolonged</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<b>Cardiac arrest, prolonged</b>
<b>:</b></b>
<b>IV:</b> 1 mEq/kg/dose once; repeat doses should be guided by arterial blood gases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956224']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956224'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Routine use of sodium bicarbonate </b>
<b>is not recommended.</b> May be considered in the setting of prolonged cardiac arrest only after adequate alveolar ventilation has been established and effective cardiac compressions. <b>Note:</b> In some cardiac arrest situations (eg, metabolic acidosis, hyperkalemia, or sodium channel blocker [eg, tricyclic antidepressant] overdose), sodium bicarbonate may be beneficial.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3e795c4b-a35d-42ad-9916-62ce3fc79053">Cardiac conduction delays due to sodium channel blockade in overdose</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cardiac conduction delays due to sodium channel blockade in overdose (off-label use): Note: </b>The optimal dose has not been established (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33081529','lexi-content-ref-26159649']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33081529','lexi-content-ref-26159649'])">Ref</a></span>). Also, the optimal QRS threshold at which to initiate therapy has not been established; some experts recommend initiating therapy if the QRS interval is &gt;100 msec (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wax.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wax.1'])">Ref</a></span>), whereas others state a threshold of &gt;120 msec (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33081529']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33081529'])">Ref</a></span>). Consultation with a clinical toxicologist or poison control center is highly recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Initial</b>
<b>:</b>
<b>IV: </b>50 to 100 mEq <b>or </b>1 to 2 mEq/<b>kg</b> over 1 to 2 minutes; repeat as needed to achieve narrowing of the QRS interval while maintaining a blood pH of 7.45 to 7.55. May initiate a continuous infusion following initial bolus therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33081529','lexi-content-ref-26159649','lexi-content-ref-Wax.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33081529','lexi-content-ref-26159649','lexi-content-ref-Wax.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous infusion: IV: </b>Following initial bolus therapy, initiate a continuous infusion using sodium bicarbonate (8.4%) 150 mEq in 1 L D5W. Administer at a rate of ~150 mL/hour to maintain a serum pH of 7.45 to 7.55. Avoid fluid overload (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33081529','lexi-content-ref-26159649','lexi-content-ref-Wax.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33081529','lexi-content-ref-26159649','lexi-content-ref-Wax.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="637f3b98-5df7-446f-8c61-563a0b944ec9">Hyperkalemia, severe/emergent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia</b>
<b>, severe/emergent (adjunctive agent) (off-label use):</b>
<b>Note: </b>Practice may vary; refer to institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hyperkalemia with cardiac arrest:</b> Intermittent bolus: <b>IV:</b> 50 mEq over 5 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956228'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hyperkalemia with metabolic acidosis:</b>
<b>Note:</b> May consider in patients with persistent severe hyperkalemia and/or ECG changes despite calcium and other therapies to decrease serum potassium, particularly in patients with metabolic acidosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33081529','lexi-content-ref-32852924','lexi-content-ref-Mount.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33081529','lexi-content-ref-32852924','lexi-content-ref-Mount.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 150 mEq in 1 L of D5W over 2 to 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1552710','lexi-content-ref-Mount.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1552710','lexi-content-ref-Mount.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="735983ed-48dc-471c-8313-6667a32eaaad">Metabolic acidosis, acute severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Metabolic </b>
<b>acidosis, acute severe:</b>
<b>Note:</b> Must treat underlying cause; the underlying cause and degree of acidosis may result in the need for larger or smaller bicarbonate replacement doses. Consider bicarbonate therapy in patients with either a pH of &lt;7.1 <b>or</b> in patients with severe acute kidney injury and a pH of ≤7.2. In most cases, the initial goal of therapy is to maintain a target pH &gt;7.2 until the primary process causing metabolic acidosis is resolved. In patients with a pH of ≤7.2 and severe acute kidney injury, the initial pH goal is &gt;7.3 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Emmett.1','lexi-content-ref-29910040','lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Emmett.1','lexi-content-ref-29910040','lexi-content-ref-34599691'])">Ref</a></span>). Optimal dosing, regimens, administration, and monitoring have not been identified; refer to institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Example regimens:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Intermittent therapy:</b> 7.5% or 8.4% sodium bicarbonate: <b>IV:</b> Initial: 89.2 to 100 mEq once over 1 to 2 minutes; reassess pH, serum bicarbonate level, and clinical status every 2 hours. If pH remains below target (~7.2 to 7.3), administer an additional 44.6 to 100 mEq sodium bicarbonate or initiate a continuous infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Emmett.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Emmett.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Example: 100 mEq of 8.4% sodium bicarbonate once over 1 to 2 minutes, then repeat with 50 to 100 mEq or initiate a continuous infusion if pH remains below target (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Emmett.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Emmett.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Continuous infusion therapy:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Bicarbonate deficit regimen: Note:</b> Dosing is based on the following bicarbonate deficit formula. This equation provides a very rough estimate of the initial bicarbonate replacement dose; monitor clinical status closely. Some experts prefer intermittent bolus therapy over continuous infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Emmett.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Emmett.1'])">Ref</a></span>). <b></b></p>
<p style="text-indent:-2em;margin-left:8em;">Continuous infusion:<b> IV: </b>Sodium bicarbonate estimated dose (mEq) = 0.5 × weight (kg) × [goal serum bicarbonate – observed serum bicarbonate (mEq/L)]; generally, goal serum bicarbonate is ~8 to 12 mEq/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9420343','lexi-content-ref-22945490','lexi-content-ref-18322160']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9420343','lexi-content-ref-22945490','lexi-content-ref-18322160'])">Ref</a></span>). <b>Note: </b>In the equation above, "0.5 × weight (kg)" represents the estimated bicarbonate V<sub>d</sub>.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note: </b>Administer the calculated amount of bicarbonate (mEq) over several hours (eg, 2 to 4 hours) until pH is ~7.2 to 7.3; reassess pH, serum bicarbonate level, and clinical status every 2 hours, and adjust dose as needed until goals are reached (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Emmett.1','lexi-content-ref-22945490']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Emmett.1','lexi-content-ref-22945490'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Example: For estimated bicarbonate deficit of 150 mEq, administer sodium bicarbonate [8.4%] 150 mEq in 1 L D5W over 2 to 4 hours, then reassess pH, serum bicarbonate level, and clinical status. Adjust dose if pH remains below target (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Emmett.1','lexi-content-ref-22945490']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Emmett.1','lexi-content-ref-22945490'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c2780b49-1e3b-494f-9033-aceaae2ba8de">Metabolic acidosis in patients with chronic kidney disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Metabolic acidosis in patients with chronic kidney disease (off-label dose): Note:</b> Kidney Disease Improving Global Outcomes guidelines suggest oral replacement when plasma HCO<sub>3</sub>
<sup>-</sup> concentrations are &lt;22 mEq/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.2013']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.2013'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 15.4 to 23.1 mEq/day in divided doses (eg, 650 mg tablet 2 to 3 times daily); titrate to normal serum bicarbonate concentrations (eg, 23 to 29 mEq/L, although a more targeted range of 24 to 26 mEq/L has been suggested by observational studies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25896890','lexi-content-ref-31036389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25896890','lexi-content-ref-31036389'])">Ref</a></span>)) or up to 5,850 mg/day; sodium bicarbonate powder may be used as an alternative in patients who cannot take tablets (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23932089','lexi-content-ref-KDIGO.2013','lexi-content-ref-19015169','lexi-content-ref-26776539']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23932089','lexi-content-ref-KDIGO.2013','lexi-content-ref-19015169','lexi-content-ref-26776539'])">Ref</a></span>). Avoid exceeding serum bicarbonate concentrations &gt;29 mEq/L since this has been associated with increased mortality in patients with chronic kidney disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19015169','lexi-content-ref-31036389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19015169','lexi-content-ref-31036389'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2059a61c-2361-4ede-b8a0-53c626d6039c">Neutralize lidocaine with epinephrine dental anesthetic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutralize lidocaine with epinephrine dental anesthetic:</b> Neutralizing additive: Mix 10 parts anesthetic (lidocaine with epinephrine) to 1 part 8.4% sodium bicarbonate.</p>
<p style="text-indent:-2em;margin-left:4em;">Add 0.18 mL sodium bicarbonate to 1.8 mL cartridge of lidocaine 2% with epinephrine 1:50,000 or 1:100,000.</p>
<p style="text-indent:-2em;margin-left:4em;">Add 2 mL sodium bicarbonate to 20 mL vial of lidocaine 2% with epinephrine 1:100,000.</p>
<p style="text-indent:-2em;margin-left:4em;">Add 3 mL sodium bicarbonate to 30 mL vial of lidocaine 2% with epinephrine 1:100,000.</p>
<p style="text-indent:-2em;margin-left:4em;">Add 5 mL sodium bicarbonate to 50 mL vial of lidocaine 2% with epinephrine 1:100,000.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ebee56c-4cc1-4ac3-9012-884f7ed8a8b1">Prevention of contrast-induced nephropathy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prevention of contrast-induced nephropathy (off-label use):</b>
<b>IV infusion:</b> 154 mEq/L sodium bicarbonate in D5W solution: 3 mL/kg/hour for 1 hour immediately before contrast injection, then 1mL/kg/hour during contrast exposure and for 6 hours after procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15150204']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15150204'])">Ref</a></span>). Some have described a prophylactic strategy based on patient risk for contrast induced nephropathy and procedure type (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19181651']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19181651'])">Ref</a></span>). <b>Note:</b> In patients at high risk for renal complications, no benefit was seen with IV sodium bicarbonate over IV sodium chloride in one study; therefore, some consider IV sodium chloride as the preferred option due to lower cost and no need for compounding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29443675','lexi-content-ref-29130810']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29443675','lexi-content-ref-29130810'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f45e942-2de1-4433-a269-dbe8a637db6e">Renal tubular acidosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal tubular acidosis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Distal</i>
<i>(off-label dose):</i>
<b>Oral</b>: Initial: 1 to 2 mEq/kg/day in up to 4 divided doses; titrate as necessary to maintain serum bicarbonate in the target range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33367987','lexi-content-ref-27188519','lexi-content-ref-33914889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33367987','lexi-content-ref-27188519','lexi-content-ref-33914889'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Proximal</i>
<i> (off-label dose):</i>
<b>Oral: </b>Initial: 10 to 15 mEq/kg/day in up to 4 divided doses; titrate as necessary to maintain serum bicarbonate in the target range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36729281','lexi-content-ref-33367987','lexi-content-ref-27188519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36729281','lexi-content-ref-33367987','lexi-content-ref-27188519'])">Ref</a></span>). <b>Note:</b> Large, infrequent doses may lead to excess bicarbonate loss in the urine; hence smaller, more frequent dosing is preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bockenhauer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bockenhauer.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c8009702-aee1-4d46-998f-b4cafc50f8ca">Urine alkalinization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urine alkalinization (off-label dose): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 48 mEq (4 g), then 12 to 24 mEq (1 to 2 g) every 4 hours; dose should be titrated to desired urinary pH; doses up to 186 mEq/day (15.6 g/day) in patients &lt;60 years of age and 92.9 mEq/day (7.8 g/day) in patients &gt;60 years of age. Administration of 48 mEq (4 g) every 8 hours has also been shown to achieve a urinary pH of at least 7 after a period of 10 hours in one study of healthy volunteers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24055481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24055481'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Urine alkalinization for high-dose methotrexate:</i>
<b>Oral:</b> 1.3 g every 4 hours while awake beginning the morning of scheduled admission day, followed by IV hydration containing sodium bicarbonate after admission (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22075004']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22075004'])">Ref</a></span>) <b>or</b> 1.3 to 1.5 g every 6 hours (with IV hydration with Lactated Ringer's) beginning in the evening prior to high-dose methotrexate administration; if the urine pH failed to reach the target (pH ≥7), the dose could be escalated to 6.5 g every 6 hours, and further escalated up to 10 g every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34471970']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34471970'])">Ref</a></span>). Sodium bicarbonate has also been used in combination with acetazolamide to facilitate urine alkalization in the ambulatory setting or in instances of IV sodium bicarbonate shortages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31507329','lexi-content-ref-35127480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31507329','lexi-content-ref-35127480'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV (off label): Note: </b>IV administration is recommended for the treatment of specific overdoses (eg, salicylates) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15083932']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15083932'])">Ref</a></span>); consultation with a clinical toxicologist or poison control center is highly recommended.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Initial:</b>
<b>Note:</b> May consider use of initial bolus doses prior to initiation of a continuous infusion, especially in patients with preexisting acidemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15083932','lexi-content-ref-Wax.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15083932','lexi-content-ref-Wax.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV: </b>50 to 100 mEq or 1 to 2 mEq/kg over 1 to 2 minutes; repeat as needed to achieve a urinary pH of 7.5 to 8.5 and a serum pH of 7.45 to 7.55 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15083932','lexi-content-ref-Wax.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15083932','lexi-content-ref-Wax.1'])">Ref</a></span>). Initiate a continuous infusion following initial bolus therapy (if used) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15083932','lexi-content-ref-Wax.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15083932','lexi-content-ref-Wax.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Continuous infusion: IV: </b>Initiate a continuous infusion using sodium bicarbonate (8.4%) 150 mEq in 1 L D5W. Administer at a rate of ~150 mL/hour to maintain a urinary pH of 7.5 to 8.5 and a serum pH of 7.45 to 7.55. Avoid fluid overload (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wax.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wax.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F51962611"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Note:</b> Contains sodium; use with caution, especially in patients with concomitant hypertension, heart failure, or volume overload (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23932089']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23932089'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F51962612"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution, especially in clinical states associated with edema and sodium retention.</p></div>
<div class="block adr drugH1Div" id="F221585"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Cardiac failure (exacerbation), edema</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Cerebral hemorrhage</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Acidosis (intracranial), hypernatremia, hypocalcemia, hypokalemia, metabolic alkalosis, milk-alkali syndrome (especially with renal dysfunction)</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Abdominal distention, eructation, flatulence (oral administration)</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Tetany</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Pulmonary edema</p></div>
<div class="block coi drugH1Div" id="F221599"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: Chloride loss due to vomiting or from continuous GI suction; concomitant use of diuretics known to produce a hypochloremic alkalosis.</p>
<p style="text-indent:-2em;margin-left:2em;">Neutralizing additive (dental or IV use): Not for use as a systemic alkalizer.</p>
<p style="text-indent:-2em;margin-left:2em;">OTC labeling: When used for self-medication, do not use if on low-sodium diet.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F221582"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Vesicant (at concentrations ≥8.4%); ensure proper catheter or needle position prior to and during infusion. Avoid extravasation (tissue necrosis may occur due to hypertonicity and alkalinity) (Ong 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cirrhosis: Use with caution in patients with cirrhosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Edema: Use with caution in patients with edema.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: Use with caution in patients with heart failure.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peptic ulcer disease: Not to be used in treatment of peptic ulcer disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Use with caution in patients with kidney impairment; may cause sodium retention.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Not the antacid of choice for the older adults because of sodium content and potential for systemic alkalosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Rapid administration in neonates, infants, and children &lt;2 years of age has led to hypernatremia, decreased CSF pressure, and intracranial hemorrhage.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Injection: Use of IV sodium bicarbonate should be reserved for documented severe metabolic acidosis and for severe/emergent hyperkalemia (eg, cardiotoxicity or cardiac arrest). Routine use in cardiac arrest is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Powder/Tablets: Completely dissolve in water prior to administration; severe stomach irritation may occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Self-medication (OTC use): Antacid: When used for self-medication (OTC), ask health care provider prior to use if on a sodium-restricted diet. Discontinue use and notify health care provider if the maximum dosage has been used for 2 weeks or severe abdominal pain occurs with use. Do not administer when overly full from food or drink.</p></div>
<div class="block dosfc drugH1Div" id="F21963630"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Sodium bicarbonate solution 4.2% [42 mg/mL] provides 0.5 mEq/mL each of sodium and bicarbonate</p>
<p style="text-indent:-2em;margin-left:2em;">Sodium bicarbonate solution 7.5% [75 mg/mL] provides 0.9 mEq/mL each of sodium and bicarbonate</p>
<p style="text-indent:-2em;margin-left:2em;">Sodium bicarbonate solution 8.4% [84 mg/mL] provides 1 mEq/mL each of sodium and bicarbonate</p></div>
<div class="block foc drugH1Div" id="F221592"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Powder, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic:  (1 g [DSC], 113 g, 454 g, 500 g, 1000 g, 2500 g, 10000 g, 12000 g, 24000 g, 25000 g, 45000 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4.2% (5 mL, 10 mL); 8.4% (10 mL, 50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4.2% (5 mL); 7.5% (50 mL); 8.4% (50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 325 mg, 650 mg</p></div>
<div class="block geq drugH1Div" id="F221578"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F5687043"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Sodium Bicarbonate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4.2% (per mL): $1.86 - $4.95</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5% (per mL): $0.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8.4% (per mL): $0.15 - $0.52</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Sodium Bicarbonate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">325 mg (per each): $0.01 - $0.05</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">650 mg (per each): $0.01 - $0.05</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868257"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4.2% (5 mL, 10 mL); 7.5% (50 mL); 8.4% (10 mL, 50 mL)</p></div>
<div class="block adip drugH1Div" id="F53568695"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">1 mEq NaHCO<sub>3</sub> is equivalent to 84 mg; each g of NaHCO<sub>3</sub> provides 12 mEq each of sodium and bicarbonate ions; the osmolarity of 0.5 mEq/mL is 1,000 mOsm/L and 1 mEq/mL is 2,000 mOsm/L.</p>
<p style="text-indent:0em;margin-top:2em;">Baking Soda powder: Each teaspoon contains 59 mEq (1,232 mg) of sodium and 59 mEq of bicarbonate (Al-Abri 2013; Taal 2012).</p>
<p style="text-indent:0em;margin-top:2em;">Oral tablets (650 mg): Each 650 mg tablet contains 7.7 mEq of sodium and 7.7 mEq of bicarbonate.</p></div>
<div class="block admp drugH1Div" id="F52613862"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Powder for solution (baking soda): Measure dose exactly, mix with adequate amount of water (eg, <sup>1</sup>/<sub>2</sub> teaspoon powder with 4 ounces of water), allow to dissolve completely prior to administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Neutralizing additive (dental use): Add specified volume of 8.4% sodium bicarbonate directly with lidocaine and epinephrine injection and mix; use immediately after mixing.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">Direct IV injection:</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates and Infants: Administer 0.5 mEq/mL solution; infusion rate depends upon indication, see dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Domonoske.1','lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Domonoske.1','lexi-content-ref-31871244'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: Administer 1 mEq/mL solution; infusion rate depends upon indication, see dosing; maximum rate: 10 mEq/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IV infusion: Infusion time variable based upon indication; may be added to IV fluids for infusion when urgent correction is not needed; for metabolic acidosis, infusions over 4 to 8 hours have been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>); in neonates, the maximum rate of administration: 1 mEq/kg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Domonoske.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Domonoske.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Vesicant (at concentrations ≥8.4%); ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote (see "Management of Drug Extravasations" for more details); remove needle/cannula; apply dry cold compresses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15192356','lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15192356','lexi-content-ref-24420913'])">Ref</a></span>); elevate extremity.</p>
<p style="text-indent:-2em;margin-left:2em;">Topical: Paste, compress/dressing: Apply to clean affected area.</p></div>
<div class="block adm drugH1Div" id="F221596"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> For direct IV infusion in emergencies, administer slowly; for infusion, dilute to a maximum concentration of 0.5 mEq/mL in dextrose solution and infuse over at least 2 hours (maximum rate of administration: 1 mEq/kg/hour).</p>
<p style="text-indent:-2em;margin-left:4em;">Vesicant (at concentrations ≥8.4%); ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately; leave needle/cannula in place temporarily but do <b>NOT</b> flush the line; gently aspirate extravasated solution, then remove needle/cannula; elevate extremity; apply dry warm compresses; initiate hyaluronidase antidote (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33141794','lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33141794','lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hyaluronidase:</i>
<b>Intradermal or SUBQ:</b> Inject a total of 1 mL (15 units/mL) as 5 separate 0.2 mL injections (using a tuberculin syringe) around the site of extravasation; if IV catheter remains in place, administer IV through the infiltrated catheter; may repeat in 30 to 60 minutes if no resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Powder: Do not administer when overly full from food or drink. Dissolve ½ teaspoonful of powder completely in 120 mL of water prior to administering.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet: Do not administer when overly full from food or drink. May be swallowed whole or dissolved completely in a glass of water prior to administering. Administration instructions differ by product; refer to product-specific labeling for additional administration instructions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Infiltration (dental use; Onpharma):</b> Add specified volume of 8.4% sodium bicarbonate directly with lidocaine and epinephrine injection and mix; use immediately after mixing.</p></div>
<div class="block sts drugH1Div" id="F221607"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Injection:</b> Store at 20°C to 25°C (68°F to 77°F). Protect from freezing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Store at 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block usep drugH1Div" id="F53568895"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Relieve conditions of gastric hyperacidity including acid indigestion, heartburn, sour stomach, or upset stomach associated with these symptoms (OTC: Powder: FDA approved in ages ≥6 years and adults; Tablets: FDA approved in adults); has also been used for management of renal tubular acidosis (RTA) and acidosis secondary to chronic kidney disease (CKD). <b>Note:</b> Approved ages and uses for generic products may vary; consult labeling for specific information.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Management of metabolic acidosis; as an alkalinization agent for the urine; management of overdose of certain drugs; management of bicarbonate loss associated with severe diarrhea (All indications: FDA approved in all ages); has also been used for management of hyperkalemia.</p>
<p style="text-indent:-2em;margin-left:4em;">Neutralizing additive:</p>
<p style="text-indent:-2em;margin-left:6em;">Local anesthetic additive (lidocaine with epinephrine): Additive to lidocaine with epinephrine solution to adjust to a more physiologic pH to improve onset of analgesia and reduce injection site pain (FDA approved in all ages).</p>
<p style="text-indent:-2em;margin-left:6em;">Parenteral neutralizing additive (eg, Neut): Additive to acidic intravenous solutions to raise pH and reduce patient discomfort and incidence of phlebitis (FDA approved in all ages). <b>Note:</b> Consult product-specific labeling of acidic IV solution for specific FDA approval ages.</p>
<p style="text-indent:-2em;margin-left:2em;">Topical: Used as a skin protectant and minor irritation relief due to poison ivy, oak, and sumac or insect bites (OTC: Powder: FDA approved in ages ≥2 years and adults).</p></div>
<div class="block cyt drugH1Div" id="F13300051"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F221587"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: Antacids may decrease the serum concentration of Acalabrutinib.  Management: Separate administration of acalabrutinib capsules from the administration of any antacid by at least 2 hours in order to minimize the potential for a significant interaction. Acalabrutinib tablets are not expected to interact with antacids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">AcetaZOLAMIDE: May enhance the adverse/toxic effect of Sodium Bicarbonate (Systemic). Specifically, the risk of renal calculus formation may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists (Indirect-Acting): Alkalinizing Agents may increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: Alkalinizing Agents may increase the serum concentration of Amantadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: Alkalinizing Agents may decrease the excretion of Amphetamines.  Management: Consider alternatives to using amphetamines and alkalinizing agents in combination. If these agents must be used together, patients should be monitored closely for excessive amphetamine effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Phenothiazines): Antacids may decrease the absorption of Antipsychotic Agents (Phenothiazines). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: Antacids may decrease the absorption of Atazanavir.  Management: Administer antacids 1 to 2 hours before or 2 hours after atazanavir to minimize the risk of a clinically significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belumosudil: Antacids may decrease the serum concentration of Belumosudil.  Management: Consider separating administration of belumosudil and antacids by 2 hours and monitor for reduced belumosudil efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisacodyl: Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine.  Gastric irritation and/or cramps may occur.  Management: Antacids should not be used within 1 hour before bisacodyl administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bismuth Subcitrate: Antacids may diminish the therapeutic effect of Bismuth Subcitrate.  Management: Avoid administration of antacids within 30 minutes of bismuth subcitrate (tripotassium bismuth dicitrate) administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: Antacids may decrease the serum concentration of Bosutinib.  Management: Administer antacids more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: Antacids may decrease the absorption of Bromperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Captopril: Antacids may decrease the serum concentration of Captopril. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefditoren: Antacids may decrease the serum concentration of Cefditoren. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefpodoxime: Antacids may decrease the serum concentration of Cefpodoxime. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefuroxime: Antacids may decrease the serum concentration of Cefuroxime.  Management: Administer cefuroxime axetil at least 1 hour before or 2 hours after the administration of short-acting antacids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroquine: Antacids may decrease the serum concentration of Chloroquine.  Management: Separate the administration of antacids and chloroquine by at least 4 hours to minimize any potential negative impact of antacids on chloroquine bioavailability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Oral): Antacids may decrease the bioavailability of Corticosteroids (Oral).  Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cysteamine (Systemic): Antacids may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: Antacids may decrease the serum concentration of Dabigatran Etexilate.  Management: Dabigatran etexilate Canadian product labeling recommends avoiding concomitant use with antacids for 24 hours after surgery. In other situations, administer dabigatran etexilate 2 hours prior to antacids. Monitor clinical response to dabigatran therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: Antacids may decrease the serum concentration of Dasatinib.  Management: Simultaneous administration of dasatinib and antacids should be avoided. Administer antacids 2 hours before or 2 hours after dasatinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: Antacids may decrease the serum concentration of Delavirdine.  Management: Separate doses of delavirdine and antacids by at least 1 hour. Monitor for decreased delavirdine therapeutic effects with this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: Antacids may decrease the serum concentration of Erlotinib.  Management: Separate the administration of erlotinib and any antacid by several hours in order to minimize the risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flecainide: Sodium Bicarbonate (Systemic) may decrease the excretion of Flecainide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosinopril: Antacids may decrease the serum concentration of Fosinopril.  Management: The US and Canadian fosinopril manufacturer labels recommend separating the doses of antacids and fosinopril by 2 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: Antacids may decrease the serum concentration of Gefitinib.  Management: Administer gefitinib at least 6 hours before or 6 hours after administration of an antacid, and closely monitor clinical response to gefitinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyoscyamine: Antacids may decrease the serum concentration of Hyoscyamine.  Management: Administer immediate release and sublingual oral hyoscyamine before meals, and antacids after meals, when these agents are given in combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: Antacids may decrease serum concentrations of the active metabolite(s) of Infigratinib. Antacids may decrease the serum concentration of Infigratinib.  Management: Avoid coadministration of infigratinib with antacids or other gastric acid-lowering agents. If antacids cannot be avoided, administer infigratinib 2 hours before or after administration of antacids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iron Preparations: Antacids may decrease the absorption of Iron Preparations.  Management: No action is likely necessary for the majority of patients who only use antacids intermittently or occasionally. Consider separating doses of oral iron and antacids in patients who require chronic use of both agents and monitor for reduced iron efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoniazid: Antacids may decrease the absorption of Isoniazid. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: Antacids may decrease the serum concentration of Itraconazole. Antacids may increase the serum concentration of Itraconazole.  Management: Administer Sporanox brand itraconazole at least 2 hours before or 2 hours after administration of any antacids. Exposure to Tolsura brand itraconazole may be increased by antacids; consider itraconazole dose reduction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): Antacids may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer antacids at least 1 hour prior to, or 2 hours after, ketoconazole. Additionally, administer ketoconazole with an acidic beverage (eg, non-diet cola) and monitor patients closely for signs of inadequate clinical response to ketoconazole.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lanthanum: Antacids may diminish the therapeutic effect of Lanthanum.  Management: Administer antacid products at least 2 hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ledipasvir: Antacids may decrease the serum concentration of Ledipasvir.  Management: Separate the administration of ledipasvir and antacids by 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: Antacids may decrease the absorption of Levoketoconazole.  Management: Advise patients to take antacids at least 2 hours after taking levoketoconazole.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonadifloxacin: Antacids may decrease the serum concentration of Levonadifloxacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Alkalinizing Agents may increase the serum concentration of Mecamylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Memantine: Alkalinizing Agents may increase the serum concentration of Memantine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mesalamine: Antacids may diminish the therapeutic effect of Mesalamine. Antacid-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Avoid concurrent administration of antacids with the Apriso brand of mesalamine extended-release capsules. The optimal duration of dose separation is unknown. Other mesalamine products do not contain this interaction warning.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methenamine: Antacids may diminish the therapeutic effect of Methenamine.  Management: Consider avoiding the concomitant use of medications that alkalinize the urine, such as antacids, and methenamine. Monitor for decreased therapeutic effects of methenamine if used concomitant with antacids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): Antacids may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, antacids may decrease the absorption of orally administered iron.  Management: Separate dosing of oral iron-containing multivitamins and antacids by as much time as possible to minimize impact of this interaction. Monitor for decreased therapeutic efficacy of oral iron preparations during coadministration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: Antacids may decrease the serum concentration of Neratinib. Specifically, antacids may reduce neratinib absorption.  Management: Separate the administration of neratinib and antacids by giving neratinib at least 3 hours after the antacid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: Antacids may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and any antacid by at least 2 hours whenever possible in order to minimize the risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: Antacids may decrease the serum concentration of Nirogacestat.  Management: If acid-reducing therapy is required, separate nirogacestat administration from antacids by 2 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Octreotide: Antacids may decrease the serum concentration of Octreotide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: Antacids may decrease the serum concentration of PAZOPanib.  Management: Avoid the use of antacids in combination with pazopanib whenever possible. Separate doses by several hours if antacid treatment is considered necessary. The impact of dose separation has not been investigated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: Antacids may decrease the serum concentration of Pexidartinib.  Management: Administer pexidartinib at least 2 hours before or 2 hours after antacids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphate Supplements: Antacids may decrease the absorption of Phosphate Supplements.  Management: This applies only to oral phosphate administration. Separating administration of oral phosphate supplements from antacid administration by as long as possible may minimize the interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Phosphate: Antacids may decrease the serum concentration of Potassium Phosphate.  Management: Consider separating administration of antacids and oral potassium phosphate by at least 2 hours to decrease risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: Alkalinizing Agents may increase the serum concentration of QuiNIDine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: Alkalinizing Agents may increase the serum concentration of QuiNINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilpivirine: Antacids may decrease the serum concentration of Rilpivirine.  Management: Administer antacids at least 2 hours before or 4 hours after oral rilpivirine when used with most rilpivirine products. However, administer antacids at least 6 hours before or 4 hours after the rilpivirine/dolutegravir combination product.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: Antacids may decrease the serum concentration of Riociguat.  Management: Separate the administration of antacids and riociguat by at least 1 hour in order to minimize any potential interaction. Monitor clinical response to riociguat more closely in patients using this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rosuvastatin: Antacids may decrease the serum concentration of Rosuvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: Antacids may decrease the serum concentration of Selpercatinib.  Management: Coadministration of selpercatinib and antacids should be avoided. If coadministration cannot be avoided, selpercatinib should be administered 2 hours before or 2 hours after antacids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. Specifically, the risk of  metabolic alkalosis may be increased. Antacids may diminish the therapeutic effect of Sodium Polystyrene Sulfonate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotalol: Antacids may decrease the serum concentration of Sotalol.  Management: Avoid simultaneous administration of sotalol and antacids. Administer antacids 2 hours after sotalol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotorasib: Antacids may decrease the serum concentration of Sotorasib.  Management: Avoid coadministration of sotorasib and antacids. If use of a gastric acid suppressing medication cannot be avoided, administer sotorasib 4 hours before or 10 hours after oral antacid administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: Antacids may decrease the serum concentration of Sparsentan.  Management: Administer sparsentan 2 hours before or 2 hours after antacids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sucralfate: Antacids may diminish the therapeutic effect of Sucralfate.  Management: Consider separating the administration of antacids and sucralfate by at least 30 minutes.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: Antacids may decrease the serum concentration of Sulpiride.  Management: Separate administration of antacids and sulpiride by at least 2 hours in order to minimize the impact of antacids on sulpiride absorption.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: Antacids may decrease the absorption of Tetracyclines.  Management: Separate administration of antacids and oral tetracycline derivatives by several hours when possible to minimize the extent of this potential interaction. Monitor for decreased therapeutic effects of tetracyclines.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Antacids may decrease the absorption of Thyroid Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Velpatasvir: Antacids may decrease the serum concentration of Velpatasvir.  Management: Separate administration of velpatasvir and antacids by at least 4 hours.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block dic drugH1Div" id="F221601"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain sodium. Oral product should be taken 1 to 3 hours after meals.</p></div>
<div class="block pri drugH1Div" id="F13888241"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Medications used for the treatment of cardiac arrest in pregnancy are the same as in the nonpregnant woman. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines. Appropriate medications should not be withheld due to concerns of fetal teratogenicity (Campbell 2009; Jeejeebhoy [AHA] 2015). Antacids containing sodium bicarbonate should not be used during pregnancy due to their potential to cause metabolic alkalosis and fluid overload in the mother and fetus (Body 2016; Dağlı 2017; Gomes 2018; Thélin 2020).</p></div>
<div class="block mopp drugH1Div" id="F53568896"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum electrolytes including calcium, urinary pH, arterial blood gases (if indicated).</p></div>
<div class="block pha drugH1Div" id="F221581"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Dissociates to provide bicarbonate ion which neutralizes hydrogen ion concentration and raises blood and urinary pH</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">Neutralizing additive (dental use): Increases pH of lidocaine and epinephrine solution to improve tolerability and increase tissue uptake</p></div>
<div class="block phk drugH1Div" id="F221598"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Oral: 15 minutes; IV: Rapid</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: Oral: 1 to 3 hours; IV: 8 to 10 minutes</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Oral: Well absorbed</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (&lt;1%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F221602"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Sodium Bicarbonate bp</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Bicarbonato | Bicarbonato de sodio | Bicarbonato de sodio ewe | Bicarbonato de sodio I.B.C. | Bicarbonato de sodio puler | Bicarbonato sodio | Solucion molar de bicarbonato de sodio</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Bullrich salz | Natrium bikarbonat fresenius kabi | Nephrotrans</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Sodicarb | Sodinate</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Braun solute | Na bicarbonate baxter | Natribic | Sodium bicarbonate vascumed povite</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Natrium hydrocarbonicum | Sodium bicarbonate braun 8,4%</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Bibag | Bicarbon | Bicarbonato de sodio | Bicarbonato sodio | Drogasil bicarbonato de sodio | Farmacart | Sol cart b | Solucao de bicarbonato de sodio halex istar</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Alkala | Natrium Bicarbonat B. Braun | Natrium bicarbonat braun | Natrium bicarbonicum bichsel</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Bicarbonato de sodio</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Bibag | Bicarbonato de sodio | Bicarbonato sodio</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Alkaligen | Natriumhydrogenca</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Bicanorm | Bullrich salz | Min-i-jet natrium hydroxid | Natriumhydrogencarbonat B. Braun | Natriumhydrogencarbonat Baxter | Natriumhydrogencarbonat DeltaSelect | Natriumhydrogencarbonat koehler | Nephrotrans</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Bicarbonato de sodio | Bicarbonato sodico</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Natrii hydrocarb</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Apir Bicarbonato sodico | Bicarbonato | Bicarbonato brum | Bicarbonato cinfa | Bicarbonato de sodio orravan | Bicarbonato de sodio pege | Bicarbonato pyre | Bicarbonato sod Bieffe | Bicarbonato sod pg | Bicarbonato sodico | Bicarbonato sodico Braun | Bicarbonato sodico Mein | Bicarbonato sodico Viviar | Bicarbonato viviar | Venofusin bicarbonato sodico | Viaflo bicarbonato sodico</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Bicart | Na bicarb isot le | Na bicarb isot mpl | Natr bicarb medip | Natr bicarb ro | Natrium bicarbonate orion | Natriumbicarbonate Braun</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Bicarbonate de sodium aguettant | Bicarbonate de sodium B.Braun | Bicarbonate de sodium baxter | Bicarbonate de sodium biosedra | Bicarbonate de sodium cooper | Bicarbonate de Sodium Gifrer | Bicarbonate de sodium lavoisier | Bicarbonate de sodium renaudin</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Nephrotrans | Polyfusor sodium bicarbonate</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Antacimin | Sodamint</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Alkaligen | Natrium hydrogen carbonicum PM | Natrium hydrogencarbonate</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Bicarbic natricus | Bicarbonat | Meylon | Natrium bicarbonat</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Braun sodium bicarbonate</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Acidose | Auxisoda | Bicarcid | Diosis | Nabico3 | Natricarb | Nocidos | Nodosis | Rencarb | Sarpix | Sobicid ds | Sobinix | Sobisis | Sobiup | Sodabicarb | Sodafix ec | Sodakindle | Sodanet | Soddy | Sodisave</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Bicart | Sodico bicarbonato | Sodio Bicarbon | Sodio bicarbonato | Sodio bicarbonato galenica senese | Sodio Bicarbonato Marco Viti Farmaceutici | Sol Bicarbon.Sodio | Sol Bilanciata | Sol Bilanciata R+K</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Berin | Jusonin | Jutamin | Jutamin pl | Meylon | Prebinate | Sod.bicarb.bioferm | Sod.bicarb.sankei | Sodium Bicarbonate Hikari | Sodium bicarbonate merck hoei | Sodium bicarbonate nipro | Sodium Bicarbonate Towa | Tansonin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Sobisis forte | Sodium bicarbonate bp (sodavita)</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bi | Bibag | Bicart | Biocapgi | Bivontase | Cdsb | Diacart | Esbi | Latna | Solcart b | Solcartbi | Tasna</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Bicanorm</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Natrium hydrocarbonas</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Natrium hydrocarbonat</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Bicarbonate NA</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Betsol z | Betuciaven | Bicarbonat sod | Bicarnat | Tecsobin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Solcart b</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Natriumhydrocarbonate</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Natriumhydrogencarbonat koehler | Natriumhydrogenkarbonat | Nephrotrans | Sodio bicarbonato</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Bicarbonato de sodio</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Soda mint | Sodium bicarbonate atlantic | Solunate | Supracid</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Pcarb | Sidocarb | Sodamint</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Alcaneff | Binat | Natrium bicarbonicum</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Basocare | Bibag | Bicarbonato de sodio | Bicarbonato sodio Labesfal</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Bicarbonato de sodio catedral | Renacarb</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Bicarbonat de sodiu | Bicarbonat de sodiu infomed</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Natrii hydrocarb. | Sodium hydrocarbonate | Sodium hydrocarbonate eskom</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Bicart | Natriumbikarbonat evolan | Natriumbikarbonat Fresenius Kabi | Natriumbikarbonat recip | Natriumbikoarbonat Recip</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Natrium hydrocarbonicum</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Arc mint | Arcsoda | Gasotab | Sodamate | Sodamint | Sodamint frx</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Bicarbonate de sodium baxter | Serum bicarbonate</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Molar sodium bicarbonat | Molar sodyum bikarbonat osel | Norm asidoz | Sodium bicarbonate molar | Sodyum bikarbonat</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Bicarbona | Bicart | Compound sodium bicarbonate | Meylon | Naturalyte 4000 | Naturalyte 9000 | Rolikan | Sodium Bicarbonate Compound | Stomach</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Natrium bicarbonat | Natrium hydrocarbonate | Natrium hydrocarbonicum | Soda bufer</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Bicarbonato sodico | Bicarbonato sodio | Suero Bicarbonatado</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bicarbonato de sodio</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Intramed sodium bicarbonate</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Sol cart b</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-16736443">
<a name="16736443"></a>Adrogué HJ. Metabolic acidosis: pathophysiology, diagnosis and management. <i>J Nephrol</i>. 2006;19(suppl 9):S62-S69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/16736443/pubmed" id="16736443" target="_blank">16736443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9420343">
<a name="9420343"></a>Adrogué HJ, Madias NE. Management of Life-Threatening Acid-Base Disorders. Second of Two Parts. <i>N Engl J Med</i>. 1998;338(2):107-111.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/9420343/pubmed" id="9420343" target="_blank">9420343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23591957">
<a name="23591957"></a>Al-Abri SA, Olson KR. Baking soda can settle the stomach but upset the heart: case files of the Medical Toxicology Fellowship at the University of California, San Francisco. <i>J Med Toxicol</i>. 2013;9(3):255-258.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/23591957/pubmed" id="23591957" target="_blank">23591957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36729281">
<a name="36729281"></a>Albuquerque ALB, Dos Santos Borges R, Conegundes AF, et al. Inherited Fanconi syndrome. <i>World J Pediatr</i>. 2023;19(7):619-634. doi:10.1007/s12519-023-00685-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/36729281/pubmed" id="36729281" target="_blank">36729281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>American Society of Health-System Pharmacists (ASHP). Pediatric continuous infusion standards. Available at https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Pediatric-Infusion-Standards.ashx. Updated January 2021. Accessed February 15, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ArmHammer.1">
<a name="ArmHammer.1"></a>Arm and Hammer Baking Soda (sodium bicarbonate) [prescribing information]. Ewing, NJ: Church &amp; Dwight; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18829808">
<a name="18829808"></a>Aschner JL, Poland RL. Sodium Bicarbonate: Basically Useless Therapy. <i>Pediatrics</i>. 2008;122(4):831-835.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/18829808/pubmed" id="18829808" target="_blank">18829808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Barry.1">
<a name="Barry.1"></a>Barry JD. Antimalarials. In: Nelson LS, Howland MA, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS, eds. <i>Goldfrank's Toxicologic Emergencies</i>. 11th ed. McGraw-Hill; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1552710">
<a name="1552710"></a>Blumberg A, Weidmann P, Ferrari P. Effect of prolonged bicarbonate administration on plasma potassium in terminal renal failure. <i>Kidney Int</i>. 1992;41(2):369-374. doi:10.1038/ki.1992.51<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/1552710/pubmed" id="1552710" target="_blank">1552710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bockenhauer.1">
<a name="Bockenhauer.1"></a>Bockenhauer D, Lopez-Garcia SC, Walsh SB. Renal tubular acidosis. In: Emma F, Goldstein SL, Bagga A, Bates CM, Shroff R, eds. <i>Pediatric Nephrology</i>. Springer; 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27261898">
<a name="27261898"></a>Body C, Christie JA. Gastrointestinal diseases in pregnancy: nausea, vomiting, hyperemesis gravidarum, gastroesophageal reflux disease, constipation, and diarrhea. <i>Gastroenterol Clin North Am</i>. 2016;45(2):267‐283. doi:10.1016/j.gtc.2016.02.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/27261898/pubmed" id="27261898" target="_blank">27261898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16390221">
<a name="16390221"></a>Bradberry SM, Thanacoody HK, Watt BE, Thomas SH, Vale JA. Management of the cardiovascular complications of tricyclic antidepressant poisoning: role of sodium bicarbonate. <i>Toxicol Rev</i>. 2005;24(3):195-204. doi:10.2165/00139709-200524030-00012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/16390221/pubmed" id="16390221" target="_blank">16390221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19713291">
<a name="19713291"></a>Brar SS, Hiremath S, Dangas G, Mehran R, Brar SK, Leon MB. Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis. <i>Clin J Am Soc Nephrol</i>. 2009;4(10):1584-1592. doi:10.2215/CJN.03120509<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/19713291/pubmed" id="19713291" target="_blank">19713291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26159649">
<a name="26159649"></a>Bruccoleri RE, Burns MM. A literature review of the use of sodium bicarbonate for the treatment of QRS widening. <i>J Med Toxicol</i>. 2016;12(1):121-129. doi:10.1007/s13181-015-0483-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/26159649/pubmed" id="26159649" target="_blank">26159649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15767228">
<a name="15767228"></a>Brucculeri M, Kaplan J, Lande L. Reversal of citalopram-induced junctional bradycardia with intravenous sodium bicarbonate. <i>Pharmacotherapy</i>. 2005;25(1):119-122. doi:10.1592/phco.25.1.119.55630<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/15767228/pubmed" id="15767228" target="_blank">15767228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19561954">
<a name="19561954"></a>Campbell TA, Sanson TG. Cardiac Arrest and Pregnancy. <i>J Emerg Trauma Shock</i>. 2009;2(1):34-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/19561954/pubmed" id="19561954" target="_blank">19561954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Carrillo-Lopez.1">
<a name="Carrillo-Lopez.1"></a>Carrillo-Lopez H, Chavez A, Jarillo A. Acid-base disorders. In: Fuhrman B, Zimmerman J, eds.<i> Pediatric Critical Care</i>. 5th ed. Elsevier Health; 2017:chap. 76.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11483854">
<a name="11483854"></a>Chan JC, Scheinman JI, Roth KS. Consultation with the specialist: renal tubular acidosis. <i>Pediatr Rev</i>. 2001;22(8):277-287.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/11483854/pubmed" id="11483854" target="_blank">11483854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23932089">
<a name="23932089"></a>Chen W, Abramowitz MK. Treatment of metabolic acidosis in patients with CKD. <i>Am J Kidney Dis</i>. 2014;63(2):311-317. doi:10.1053/j.ajkd.2013.06.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/23932089/pubmed" id="23932089" target="_blank">23932089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31706619">
<a name="31706619"></a>Clase CM, Carrero JJ, Ellison DH, et al; Conference Participants. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney Int</i>. 2020;97(1):42-61. doi:10.1016/j.kint.2019.09.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/31706619/pubmed" id="31706619" target="_blank">31706619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24055481">
<a name="24055481"></a>Cohen B, Laish I, Brosh-Nissimov T, et al. Efficacy of urine alkalinization by oral administration of sodium bicarbonate: a prospective open-label trial. <i>Am J Emerg Med</i>. 2013;31(12):1703-1706.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/24055481/pubmed" id="24055481" target="_blank">24055481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29199169">
<a name="29199169"></a>Dağlı Ü, Kalkan İH. Treatment of reflux disease during pregnancy and lactation. <i>Turk J Gastroenterol</i>. 2017;28(suppl 1):S53‐S56. doi:10.5152/tjg.2017.14<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/29199169/pubmed" id="29199169" target="_blank">29199169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25896890">
<a name="25896890"></a>Dobre M, Yang W, Pan Q, et al; CRIC Study Investigators. Persistent high serum bicarbonate and the risk of heart failure in patients with chronic kidney disease (CKD): a report from the Chronic Renal Insufficiency Cohort (CRIC) study. <i>J Am Heart Assoc</i>. 2015;4(4):e001599. doi:10.1161/JAHA.114.001599<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/25896890/pubmed" id="25896890" target="_blank">25896890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Doherty.1">
<a name="Doherty.1"></a>Doherty EG. Fluid and electrolyte management. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th edition. Lippincott Williams &amp; Wilkins; 2017:chap 23.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Domonoske.1">
<a name="Domonoske.1"></a>Domonoske C. Appendix A: Common neonatal intensive care unit (NICU) medication guidelines. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th edition. Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12902002">
<a name="12902002"></a>Engebretsen KM, Harris CR, Wood JE. Cardiotoxicity and late onset seizures with citalopram overdose. <i>J Emerg Med</i>. 2003;25(2):163-166. doi:10.1016/s0736-4679(03)00164-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/12902002/pubmed" id="12902002" target="_blank">12902002</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Emmett.1">
<a name="Emmett.1"></a>Emmett M, Szerlip H. Approach to the adult with metabolic acidosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed November 23, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34599691">
<a name="34599691"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. <i>Intensive Care Med</i>. 2021;47(11):1181-1247. doi:10.1007/s00134-021-06506-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/34599691/pubmed" id="34599691" target="_blank">34599691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fuhrman.1">
<a name="Fuhrman.1"></a>Fuhrman B, Zimmerman J, eds. <i>Pediatric Critical Care</i>. 4th ed. Elsevier; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33770395">
<a name="33770395"></a>Giglio S, Montini G, Trepiccione F, Gambaro G, Emma F. Distal renal tubular acidosis: a systematic approach from diagnosis to treatment. <i>J Nephrol</i>. 2021;34(6):2073-2083. doi:10.1007/s40620-021-01032-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/33770395/pubmed" id="33770395" target="_blank">33770395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19181651">
<a name="19181651"></a>Goldfarb S, McCullough PA, McDermott J, Gay SB. Contrast-induced acute kidney injury: specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional cardiology. <i>Mayo Clin Proc</i>. 2009;84(2):170-179.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/19181651/pubmed" id="19181651" target="_blank">19181651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29991883">
<a name="29991883"></a>Gomes CF, Sousa M, Lourenço I, Martins D, Torres J. Gastrointestinal diseases during pregnancy: what does the gastroenterologist need to know?. <i>Ann Gastroenterol</i>. 2018;31(4):385‐394. doi:10.20524/aog.2018.0264<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/29991883/pubmed" id="29991883" target="_blank">29991883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34471970">
<a name="34471970"></a>Heisler RD, Kelly JJ, Abedinzadegan Abdi S, et al. Evaluation of an oral sodium bicarbonate protocol for high-dose methotrexate urine alkalinization. <i>Support Care Cancer</i>. 2022;30(2):1273-1281. doi:10.1007/s00520-021-06503-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/34471970/pubmed" id="34471970" target="_blank">34471970</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18245435">
<a name="18245435"></a>Howland MA. Antidotes in depth: sodium bicarbonate. In: Nelson LS, Howland MA, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS, eds. <i>Goldfrank's Toxicologic Emergencies</i>. 11th ed. McGraw-Hill; 2019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/18245435/pubmed" id="18245435" target="_blank">18245435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15192356">
<a name="15192356"></a>Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/15192356/pubmed" id="15192356" target="_blank">15192356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.1">
<a name="IOM.1"></a>IOM (Institute of Medicine). <i>Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate</i>. National Academy Press; 2004.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29910040">
<a name="29910040"></a>Jaber S, Paugam C, Futier E, et al. Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial.<i> Lancet</i>. 2018;392(10141):31-40. doi:10.1016/S0140-6736(18)31080-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/29910040/pubmed" id="29910040" target="_blank">29910040</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26443610">
<a name="26443610"></a>Jeejeebhoy FM, Zelop CM, Lipman S, et al; American Heart Association Emergency Cardiovascular Care Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Diseases in the Young, and Council on Clinical Cardiology. Cardiac Arrest in Pregnancy: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2015;132(18):1747-1773. doi:10.1161/CIR.0000000000000300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/26443610/pubmed" id="26443610" target="_blank">26443610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kaspar.1">
<a name="Kaspar.1"></a>Kaspar CDW, Bunchman TE. Glomerulotubular dysfunction and acute kidney injury. In: Fuhrman B, Zimmerman J, eds.<i> Pediatric Critical Care</i>. 5th ed. Elsevier Health; 2017:chap. 75.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.2013">
<a name="KDIGO.2013"></a>Kidney Disease Improving Global Outcomes (KDIGO). 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. <i>Kidney Int Suppl</i>. 2013;3(suppl 1):1-150. http://www.kidney-international.org. Published January 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.2012">
<a name="KDIGO.2012"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. <i>Kidney Int Suppl</i>. 2012;2(suppl 1):1-138. https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf. Published March 2012. Accessed March 15, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22075004">
<a name="22075004"></a>Kintzel PE, Campbell AD, Yost KJ, et al. Reduced time for urinary alkalinization before high-dose methotrexate with preadmission oral bicarbonate. <i>J Oncol Pharm Pract</i>. 2012;18(2):239-244. doi:10.1177/1078155211426913<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/22075004/pubmed" id="22075004" target="_blank">22075004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956230">
<a name="20956230"></a>Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>, 2010;122(18)(suppl 3):876-908.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/20956230/pubmed" id="20956230" target="_blank">20956230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19015169">
<a name="19015169"></a>Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD. <i>Nephrol Dial Transplant</i>. 2009;24(4):1232-1237. doi:10.1093/ndt/gfn633<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/19015169/pubmed" id="19015169" target="_blank">19015169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20526632">
<a name="20526632"></a>Kraut JA, Madias NE. Consequences and therapy of the metabolic acidosis of chronic kidney disease. <i>Pediatr Nephrol</i>. 2011;26(1):19-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/20526632/pubmed" id="20526632" target="_blank">20526632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22945490">
<a name="22945490"></a>Kraut JA, Madias NE. Treatment of acute metabolic acidosis: a pathophysiologic approach. <i>Nat Rev Nephrol</i>. 2012;8(10):589-601. doi:10.1038/nrneph.2012.186<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/22945490/pubmed" id="22945490" target="_blank">22945490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9733258">
<a name="9733258"></a>Liebelt EL. Targeted management strategies for cardiovascular toxicity from tricyclic antidepressant overdose: the pivotal role for alkalinization and sodium loading. <i>Pediatr Emerg Care</i>. 1998;14(4):293-298.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/9733258/pubmed" id="9733258" target="_blank">9733258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23629618">
<a name="23629618"></a>Lightdale JR, Gremse DA, Section on Gastroenterology, Hepatology, and Nutrition. Gastroesophageal reflux: management guidance for the pediatrician. <i>Pediatrics</i>. 2013;131(5):e1684-e1695.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/23629618/pubmed" id="23629618" target="_blank">23629618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32852924">
<a name="32852924"></a>Lindner G, Burdmann EA, Clase CM, et al. Acute hyperkalemia in the emergency department: a summary from a Kidney Disease: Improving Global Outcomes conference. <i>Eur J Emerg Med</i>. 2020;27(5):329-337. doi:10.1097/MEJ.0000000000000691<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/32852924/pubmed" id="32852924" target="_blank">32852924</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15036741">
<a name="15036741"></a>Lokesh L, Kumar P, Murki S, et al. A Randomized Controlled Trial of Sodium Bicarbonate in Neonatal Resuscitation-Effect on Immediate Outcome. <i>Resuscitation</i>. 2004;60(2):219-223.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/15036741/pubmed" id="15036741" target="_blank">15036741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Medis.1">
<a name="Medis.1"></a>Medis Sodium Bicarbonate (sodium bicarbonate) [prescribing information]. Texarkana, TX: Humco: June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15150204">
<a name="15150204"></a>Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. <i>JAMA</i>. 2004;291(19):2328-2334. doi:10.1001/jama.291.19.2328<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/15150204/pubmed" id="15150204" target="_blank">15150204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mount.1">
<a name="Mount.1"></a>Mount DB. Treatment and prevention of hyperkalemia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 9, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15318251">
<a name="15318251"></a>Murki S, Kumar P, Lingappa L, et al. Effect of a Single Dose of Sodium Bicarbonate Given During Neonatal Resuscitation at Birth on the Acid-Base Status on First Day of Life.<i> J Perinatol</i>. 2004;24(11):696-699.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/15318251/pubmed" id="15318251" target="_blank">15318251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956224">
<a name="20956224"></a>Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18 Suppl 3):S729-S767. doi:10.1161/CIRCULATIONAHA.110.970988<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/20956224/pubmed" id="20956224" target="_blank">20956224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Neut.1">
<a name="Neut.1"></a>Neut (sodium bicarbonate) [prescribing information]. Lake Forest, IL: Hospira; June 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Novaplus.1">
<a name="Novaplus.1"></a>Novaplus sodium bicarbonate injection [prescribing information]. Lake Forest, IL: Hospira Inc; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33141794">
<a name="33141794"></a>Ong J, Van Gerpen R. Recommendations for management of noncytotoxic vesicant extravasations. <i>J Infus Nurs</i>. 2020;43(6):319-343. doi:10.1097/NAN.0000000000000392<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/33141794/pubmed" id="33141794" target="_blank">33141794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17719303">
<a name="17719303"></a>Ozcan EE, Guneri S, Akdeniz B, et al. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. <i>Am Heart J</i>. 2007;154(3):539-544. doi:10.1016/j.ahj.2007.05.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/17719303/pubmed" id="17719303" target="_blank">17719303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33367987">
<a name="33367987"></a>Palmer BF, Kelepouris E, Clegg DJ. Renal tubular acidosis and management strategies: a narrative review. <i>Adv Ther</i>. 2021;38(2):949-968. doi:10.1007/s12325-020-01587-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/33367987/pubmed" id="33367987" target="_blank">33367987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33081529">
<a name="33081529"></a>Panchal AR, Bartos JA, Cabañas JG, et al; Adult basic and advanced life support writing group. Part 3: adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2020;142(16)(suppl 2):S366-S468. doi:10.1161/CIR.0000000000000916<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/33081529/pubmed" id="33081529" target="_blank">33081529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15083932">
<a name="15083932"></a>Proudfoot AT, Krenzelok EP, Vale JA. Position Paper on urine alkalinization. <i>J Toxicol Clin Toxicol</i>. 2004;42(1):1-26. doi:10.1081/clt-120028740<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/15083932/pubmed" id="15083932" target="_blank">15083932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26776539">
<a name="26776539"></a>Raphael KL. Approach to the Treatment of Chronic Metabolic Acidosis in CKD. <i>Am J Kidney Di</i>s. 2016;67(4):696-702.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/26776539/pubmed" id="26776539" target="_blank">26776539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31036389">
<a name="31036389"></a>Raphael KL. Metabolic acidosis in CKD: core curriculum 2019. <i>Am J Kidney Dis</i>. 2019;74(2):263-275. doi:10.1053/j.ajkd.2019.01.036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/31036389/pubmed" id="31036389" target="_blank">31036389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31507329">
<a name="31507329"></a>Reed DR, Pierce EJ, Sen JM, Keng MK. A prospective study on urine alkalization with an oral regimen consisting of sodium bicarbonate and acetazolamide in patients receiving high-dose methotrexate. <i>Cancer Manag Res</i>. 2019;11:8065-8072. doi:10.2147/CMAR.S190084<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/31507329/pubmed" id="31507329" target="_blank">31507329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26919414">
<a name="26919414"></a>Richards JR, Garber D, Laurin EG, et al. Treatment of cocaine cardiovascular toxicity: a systematic review. <i>Clin Toxicol (Phila)</i>. 2016;54(5):345-364. doi:10.3109/15563650.2016.1142090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/26919414/pubmed" id="26919414" target="_blank">26919414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12138150">
<a name="12138150"></a>Rodríguez Soriano J. Renal tubular acidosis: the clinical entity. <i>J Am Soc Nephrol</i>. 2002;13(8):2160-2170.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/12138150/pubmed" id="12138150" target="_blank">12138150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7131138">
<a name="7131138"></a>Rodríguez-Soriano J, Vallo A, Castillo G, Oliveros R. Natural history of primary distal renal tubular acidosis treated since infancy. <i>J Pediatr</i>. 1982;101(5):669-676.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/7131138/pubmed" id="7131138" target="_blank">7131138</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29470322">
<a name="29470322"></a>Rosen R, Vandenplas Y, Singendonk M, et al. Pediatric Gastroesophageal Reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. <i>J Pediatr Gastroenterol Nutr</i>. 2018;66(3):516-554. doi:10.1097/MPG.0000000000001889<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/29470322/pubmed" id="29470322" target="_blank">29470322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29443675">
<a name="29443675"></a>Rosner MH. Prevention of contrast-associated acute kidney injury. <i>N Engl J Med</i>. 2018;378(7):671-672. doi:10.1056/NEJMe1715190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/29443675/pubmed" id="29443675" target="_blank">29443675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18322160">
<a name="18322160"></a>Sabatini S, Kurtzman NA. Bicarbonate therapy in severe metabolic acidosis. <i>J Am Soc Nephrol</i>. 2009;20(4):692-695. doi:10.1681/ASN.2007121329<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/18322160/pubmed" id="18322160" target="_blank">18322160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3777038">
<a name="3777038"></a>Santos F, Chan JC. Renal tubular acidosis in children. Diagnosis, treatment and prognosis. <i>Am J Nephrol</i>. 1986;6(4):289-295.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/3777038/pubmed" id="3777038" target="_blank">3777038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12811715">
<a name="12811715"></a>Sharma AN, Hexdall AH, Chang EK, Nelson LS, Hoffman RS. Diphenhydramine-induced wide complex dysrhythmia responds to treatment with sodium bicarbonate. <i>Am J Emerg Med</i>. 2003;21(3):212-215. doi:10.1016/s0735-6757(02)42248-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/12811715/pubmed" id="12811715" target="_blank">12811715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs Used to Treat Pediatric Emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rugby.1">
<a name="Rugby.1"></a>Sodium bicarbonate 5 gr [prescribing information]. Duluth, GA: Rugby Laboratories Inc; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-International.1">
<a name="International.1"></a>Sodium bicarbonate injection [prescribing information]. El Monte, CA: International Medication Systems Ltd; January 2008.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-International.2">
<a name="International.2"></a>Sodium bicarbonate injection [prescribing information]. El Monte, CA: International Medication Systems Ltd; September 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.6">
<a name="Hospira.6"></a>Sodium bicarbonate injection, solution [prescribing information]. Lake Forest, IL: Hospira Inc; January 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.7">
<a name="Hospira.7"></a>Sodium bicarbonate injection, solution 4.2% syringe [prescribing information]. Lake Forest, IL: Hospira Inc; January 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.5">
<a name="Hospira.5"></a>Sodium bicarbonate injection, solution 4.2% vial [prescribing information]. Lake Forest, IL: Hospira Inc; February 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fresenius.1">
<a name="Fresenius.1"></a>Sodium bicarbonate injection, solution 4.2% and 8.4% vial [prescribing information]. Lake Zurich, IL: Fresenius Kabi; June 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.4">
<a name="Hospira.4"></a>Sodium bicarbonate injection, solution 4.2%, 5%, 7.5%, and 8.4% [prescribing information]. Lake Forest, IL: Hospira Inc; October 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.3">
<a name="Hospira.3"></a>Sodium bicarbonate injection, solution 8.4% vial [prescribing information]. Lake Forest, IL: Hospira Inc; May 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.2">
<a name="Hospira.2"></a>Sodium bicarbonate injection, solution 8.4% syringe [prescribing information]. Lake Forest, IL: Hospira Inc; January 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.1">
<a name="Hospira.1"></a>Sodium bicarbonate injection, solution 7.5% and 8.4% syringe [prescribing information]. Lake Forest, IL: Hospira Inc; January 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Onpharma.1">
<a name="Onpharma.1"></a>Sodium bicarbonate neutralizing additive solution [prescribing information]. Los Gatos, CA: Onpharma; November 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Humco.1">
<a name="Humco.1"></a>Sodium bicarbonate oral powder [prescribing information]. Paramount, CA: DLC Laboratories; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rugby.2">
<a name="Rugby.2"></a>Sodium bicarbonate tablets 325 mg [prescribing information]. Livonia, MI: Rugby Laboratories; November 201.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GenDose.1">
<a name="GenDose.1"></a>Sodium bicarbonate tablets 650 mg [prescribing information]. Davidson, NC: GenDose Pharmaceuticals; received April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35127480">
<a name="35127480"></a>Sokol K, Yuan K, Piddoubny M, et al. Implementation of an outpatient HD-MTX initiative. <i>Front Oncol</i>. 2022;11:773397. doi:10.3389/fonc.2021.773397<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/35127480/pubmed" id="35127480" target="_blank">35127480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27188519">
<a name="27188519"></a>Soleimani M, Rastegar A. Pathophysiology of renal tubular acidosis: core curriculum 2016. <i>Am J Kidney Dis</i>. 2016;68(3):488-498. doi:10.1053/j.ajkd.2016.03.422<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/27188519/pubmed" id="27188519" target="_blank">27188519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21866433">
<a name="21866433"></a>Stacul F, van der Molen AJ, Reimer P, et al; Contrast Media Safety Committee of European Society Urogenital Radiology (ESUR). Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. <i>Eur Radiol</i>. 2011;21(12):2527-2541. doi:10.1007/s00330-011-2225-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/21866433/pubmed" id="21866433" target="_blank">21866433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: A focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy</i>. 2023;40(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Taal.1">
<a name="Taal.1"></a>Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu ASL, Brenner BA, eds. <i>Brenner and Rector's The Kidney</i>. 9th ed. Elsevier Saunders; 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31950535">
<a name="31950535"></a>Thélin CS, Richter JE. Review article: the management of heartburn during pregnancy and lactation. <i>Aliment Pharmacol Ther</i>. 2020;51(4):421‐434. doi:10.1111/apt.15611<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/31950535/pubmed" id="31950535" target="_blank">31950535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33081526">
<a name="33081526"></a>Topjian AA, Raymond TT, Atkins D, et al. Part 4: pediatric basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2020;142(16_suppl_2):S469-S523. doi:10.1161/CIR.0000000000000901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/33081526/pubmed" id="33081526" target="_blank">33081526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33914889">
<a name="33914889"></a>Trepiccione F, Walsh SB, Ariceta G, et al. Distal renal tubular acidosis: ERKNet/ESPN clinical practice points. <i>Nephrol Dial Transplant</i>. 2021;36(9):1585-1596. doi:10.1093/ndt/gfab171<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/33914889/pubmed" id="33914889" target="_blank">33914889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956228">
<a name="20956228"></a>Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18)(suppl 3):829-861. doi:10.1161/CIRCULATIONAHA.110.971069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/20956228/pubmed" id="20956228" target="_blank">20956228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wax.1">
<a name="Wax.1"></a>Wax PM, Haynes A. Antidotes in depth: physostigmine salicylate. In: Nelson LS, Howland MA, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS, eds. <i>Goldfrank's Toxicologic Emergencies</i>. 11th ed. McGraw-Hill; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29130810">
<a name="29130810"></a>Weisbord SD, Gallagher M, Jneid H, et al; PRESERVE Trial Group. Outcomes after angiography with sodium bicarbonate and acetylcysteine. <i>N Engl J Med</i>. 2018;378(7):603-614. doi:10.1056/NEJMoa1710933<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/29130810/pubmed" id="29130810" target="_blank">29130810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19884624">
<a name="19884624"></a>Zoungas S, Ninomiya T, Huxley R, et al. Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. <i>Ann Intern Med</i>. 2009;151(9):631-638. doi:10.7326/0003-4819-151-9-200911030-00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-bicarbonate-pediatric-drug-information/abstract-text/19884624/pubmed" id="19884624" target="_blank">19884624</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12795 Version 535.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
